Proactive Investors - Run By Investors For Investors

Allergy Therapeutics thinks its adjuvant system could be used in fight against cancer

The combination of Allergy’s Microcrystalline Tyrosine (MCT) adjuvant system with virus-like particles proved successful in mice
skin cancer
MCT has been used for years to boost the immune system of allergy sufferers

Early-stage research has shown that Allergy Therapeutics PLC’s (LON:AGY) adjuvant technology could potentially be used in the fight against cancer.

Allergy’s Microcrystalline Tyrosine (MCT) adjuvant system has long been used to help boost the immune systems of allergy sufferers.

But research carried out alongside the University of Oxford has shown that the combination of MCT and virus-like particles (VLPs) could potentially benefit people with cancer.

READ: Allergy Thera well-funded and making headway

The combination caused tumour regression in an “aggressive” melanoma (skin cancer) mouse model and initiated a “highly protective” immune response.

Typically, VLPs are quickly ‘washed away’ by the body due to their small size, but formulating them with bigger MCT meant they were exposed to the immune system for longer. This helped to induce “strong” responses from T-cells – a type of white blood cell that attacks cancer cells.

“Our strategy for growth with our adjuvant division, Bencard Adjuvant Systems, focuses on extending the use of MCT and VLPs in developing vaccines for unmet needs and disease areas beyond allergy that require an effective depot adjuvant,” said chief executive Manuel Llobet.

“This ground-breaking work, completed in collaboration with the Jenner Institute at the University of Oxford, supports this strategy and complements the existing work illustrating the potential of our adjuvant systems in disease areas such as influenza and malaria.”

Allergy shares were broadly flat at 9.2p on Tuesday.

View full AGY profile View Profile

Allergy Therapeutics PLC Timeline

Related Articles

May 09 2019
Here we take a look under the hood of Shield Therapeutics
February 28 2019
The company is a leader for dried flower vaporizers, and a pioneer in cannabis telemedicine and AI technologies
June 11 2019
Oncimmune is a specialist in the field of immunodiagnostics

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use